Six-year follow-up of CycloME and RituxME
Rekeland IG et al. · 2024 · PLOS ONE
Indexed 2026-11-12.
Reported findings and study design
Reported findings
Investigators reassessed previous participants six years after the two parent studies. Participation was 94.4% of eligible CycloME and 75.7% of eligible RituxME participants.
Dose, route and schedule
Investigators reassessed previous participants six years after the two parent studies. Participation was 94.4% of eligible CycloME and 75.7% of eligible RituxME participants.
Protocol source ↗ · Original source
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| SF-36 physical function score of at least 70 | 44.1% in CycloME, 27.6% among former RituxME rituximab participants and 20.4% among former RituxME placebo participants. |
Reuses both parent cohorts. CycloME was open-label. Comparing it with the RituxME arms is an observational, cross-trial comparison.
Source for these results ↗ · Reviewed 2026-11-12
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- Reuses both parent cohorts. CycloME was open-label. Comparing it with the RituxME arms is an observational, cross-trial comparison.
Source access
Investigators reassessed previous participants six years after the two parent studies. Participation was 94.4% of eligible CycloME and 75.7% of eligible RituxME participants.
Source reviewed 2026-11-12.
Citation and original source
Original source: Rekeland IG et al.. Six-year follow-up of CycloME and RituxME PLOS ONE 2024.
Molekul research summary: https://molekul.io/research/cyclome-rituxme-followup-2024. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry